Neuroendocrine Tumor Market

Table of Content

1. Introduction
   • Definition of Neuroendocrine Tumors Market
   • Scope of the Report
2. Methodology
   • Executive Summary
   • Market Overview
   • Market Definition and Segmentation
3. Market Dynamics
   • Drivers
   • Restraints
   • Opportunities
   • Porter's Five Forces Analysis
   • PESTEL Analysis
4. Neuroendocrine Tumors Market, By Classification
   • Functional Net
   • Non-Functional Net
5. Neuroendocrine Tumors Market, By Site
   • Lung
   • Pancreas
   • Gastrointestinal Tract (GI))
6. Neuroendocrine Tumors Market, By Grade
   • Grade 1 (Low-Grade Tumor
   • Grade 2 (Intermediate-Grade Tumor
   • Grade 3 (High-Grade Tumor))
7. Neuroendocrine Tumors Market, By Type
   • Treatment
     • Somatostatin Analogs
       • Octreotide
       • Lanreotide
     • Targeted Therapy
       • Everolimus
       • Sunitinib
       • Others
     • Radiation Therapy
       • External-Beam Radiation
       • Internal-Beam Radiation
     • Surgery
       • Cholecystectomy
       • Others
     • Liver-Directed Treatment
       • Radio Frequency Ablation (RFA)
       • Hepatic Artery Embolization
       • Radioembolization
     • Peptide Receptor Radionuclide Therapy (Prrt)/ Lutathera
   • Diagnosis
     • Blood Test
     • Imaging Test
       • CTscan
       • MRI
       • Others
     • Biopsy
     • Urine Test
     • Others
8. Neuroendocrine Tumors Market, By Route of Administration
   • Oral
     • Tablets
     • Pills
     • Others
   • Parenteral
     • Subcutaneous
     • Intramuscular
     • Others
9. Neuroendocrine Tumors Market, By End User
   • Hospitals
   • Specialty Clinics
   • Radiation Centers
   • Home Healthcare
   • Others
10. Neuroendocrine Tumors Market, By Distribution Channel
    • Direct Tender
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
11. Neuroendocrine Tumors Market, By Geography
    • North America
      • United States
      • Canada
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • Saudi Arabia
      • United Arab Emirates
      • South Africa
      • Rest of Middle East & Africa
12. Competitive Landscape
13. Company Profiles
    • F. Hoffmann-La Roche Ltd
      • Company Overview
      • Product Portfolio and Description
      • Key Highlights
      • Financial Overview
    • Bristol-Myers Squibb Company
    • Viatris Inc.
    • Thermo Fisher Scientific Inc.
    • Novartis Ag
    • Regeneron Pharmaceuticals, Inc.
    • Advanced Accelerator Applications (A Subsidiary Of Novartis Ag)
    • Bionano Genomics
    • Biosynthema Inc.
    • Callistopharma
    • Eli Lilly And Company
    • Exact Sciences Corporation
    • Glaxosmithkline Plc
    • Hutchison China Meditech Limited
    • Ipsen Pharma
    • Illumina, Inc.
    • Lupin
    • Merck Sharp & Dohme Corp., A Subsidiary Of Merck & Co., Inc.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
14. Conclusion and Future Outlook
15. Appendix
    • Research Methodology
    • About the Pharmanucleus
16. Disclaimer